Serialisation is a means to track and trace products to help overcome counterfeit drugs. Serialisation legislation is already enforced in Brazil, South Korea and China, is due to come into effect in the US in 2017, and in all European countries by Feb 2019 for all prescription drugs.
Serialisation demands are complex and vary by country. Aesica has developed a serialisation module that is flexible, scalable, and capable of printing high resolution variable data (human readable, 2-dimentional and linear barcodes), supported by advanced communication protocols for remote operation and secure serialisation.
In this second webinar, Ralf Liedke, Director of IT Germany at Aesica, will discuss serial numbers and the corresponding details of Aesica’s serialisation solution.
Viewers will learn:
- The different types of serial numbers and requirements
- How to handle data integrity on serial numbers
- How to connect to different systems, such as packaging lines and ERP systems
Ralf Liedke, PhD, IT Director Germany, Aesica Pharmaceuticals
Ralf Liedke is the IT Director Germany at Aesica Pharmaceuticals. As well as leading the German IT department, Ralf is responsible for all IT-related aspects in delivering Aesica’s serialisation capability in Germany.
Ralf has over 16 years of experience in the pharmaceutical industry, bringing together pharmaceutical business requirements and technical specifications. He previously worked in IT project and application management positions at UCB, iCD GmbH, and LGC Forensics before joining Aesica. Ralf holds a PhD in chemistry.
Who Should Attend?
Professionals in Production and Supply Chain, Outsourcing Managers, Procurement, R&D Managers
Aesica, a Consort Medical business, is a full-service partner for the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. We partner with customers to provide a flexible, efficient and dependable service that leverages our innovative approach and more than 30 years’ experience.
Our manufacturing facilities meet the highest standards according to regulatory and customer audits, allowing us to effectively manage our customers’ supply chain. We continuously invest in the latest technologies and develop our people to stay at the forefront of the industry.
As part of the Consort Medical Group, we work together with our Bespak colleagues to accelerate the route to market of drug-device combinations, through streamlined supply, for our customers at any stage of the development cycle. Across the group, we currently have 11 facilities across Europe supported by a global sales presence including North and South America, China, India, and Japan.